These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24958181)

  • 41. Understanding genomic alterations in cancer genomes using an integrative network approach.
    Wang E
    Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic.
    Statz CM; Patterson SE; Mockus SM
    Expert Rev Mol Diagn; 2017 Jun; 17(6):549-555. PubMed ID: 28402162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of surgeons in building a personalized medicine program.
    Boland GM; Meric-Bernstam F
    J Surg Oncol; 2015 Jan; 111(1):3-8. PubMed ID: 24964977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Precision Medicine and Personalized Medicine in Cardiovascular Disease.
    Currie G; Delles C
    Adv Exp Med Biol; 2018; 1065():589-605. PubMed ID: 30051409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Applications of Genomic Sequencing in Pediatric CNS Tumors.
    Bavle AA; Lin FY; Parsons DW
    Oncology (Williston Park); 2016 May; 30(5):411-23. PubMed ID: 27188671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cancer: three eras of personalized medicine].
    Jordan B
    Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Building evidence and measuring clinical outcomes for genomic medicine.
    Peterson JF; Roden DM; Orlando LA; Ramirez AH; Mensah GA; Williams MS
    Lancet; 2019 Aug; 394(10198):604-610. PubMed ID: 31395443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic medicine and risk prediction across the disease spectrum.
    Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
    Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Data resources for the identification and interpretation of actionable mutations by clinicians.
    Prawira A; Pugh TJ; Stockley TL; Siu LL
    Ann Oncol; 2017 May; 28(5):946-957. PubMed ID: 28327901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Personalized cancer genomics: the road map to clinical implementation.
    Yousef GM
    Clin Chem; 2012 Apr; 58(4):661-3. PubMed ID: 22322979
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical genomics and contextualizing genome variation in the diagnostic laboratory.
    Lupski JR; Liu P; Stankiewicz P; Carvalho CMB; Posey JE
    Expert Rev Mol Diagn; 2020 Oct; 20(10):995-1002. PubMed ID: 32954863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prioritizing diversity in human genomics research.
    Hindorff LA; Bonham VL; Brody LC; Ginoza MEC; Hutter CM; Manolio TA; Green ED
    Nat Rev Genet; 2018 Mar; 19(3):175-185. PubMed ID: 29151588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
    Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
    Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer.
    Jiang M; Yang J; Li K; Liu J; Jing X; Tang M
    Int J Med Sci; 2021; 18(3):626-638. PubMed ID: 33437197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Existing and emerging technologies for tumor genomic profiling.
    MacConaill LE
    J Clin Oncol; 2013 May; 31(15):1815-24. PubMed ID: 23589546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Translating genomics for precision cancer medicine.
    Roychowdhury S; Chinnaiyan AM
    Annu Rev Genomics Hum Genet; 2014; 15():395-415. PubMed ID: 25184532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Moving beyond genome sequencing into personalized genomic medicine: biological and computing challenges.
    Kristensen DM
    Genome Biol; 2011 Oct; 12(10):308. PubMed ID: 22023790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
    Shukla HD; Mahmood J; Vujaskovic Z
    Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.